SAB Biotherapeutics Warrant
SABSW
12 hedge funds and large institutions have $43.8K invested in SAB Biotherapeutics Warrant in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
20% more funds holding
Funds holding: 10 → 12 (+2)
3% more capital invested
Capital invested by funds: $42.6K → $43.8K (+$1.25K)
0.47% less ownership
Funds ownership: 2.69% → 2.23% (-0.47%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$333 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3 |
| 3 |
CS
Clear Street
New York
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.01K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$2.12K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$872 |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $21K | – | – | – |
|
|
SCM
2
Shaolin Capital Management
Miami,
Florida
| $11.4K | -$2.12K | -78,676 | -21% |
|
|
3
Morgan Stanley
New York
| $4.47K | -$4.01K | -148,939 | -50% |
|
|
YCM
4
Yakira Capital Management
Westport,
Connecticut
| $3.93K | – | – | – |
|
5
Walleye Capital
New York
| $907 | – | – | – |
|
|
WAM
6
Wolverine Asset Management
Chicago,
Illinois
| $888 | -$1 | -27 | -0.1% |
|
7
Walleye Trading
New York
| $605 | – | – | – |
|
|
8
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $482 | +$333 | +12,366 | New |
|
|
NA
9
NewEdge Advisors
New Orleans,
Louisiana
| $42 | – | – | – |
|
|
CS
10
Clear Street
New York
| $4 | +$3 | +100 | New |
|
|
11
Bank of America
Charlotte,
North Carolina
| $3 | +$3 | +100 | New |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $2 | – | – | – |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$872 | -29,080 | Closed |
|
SABSW Hedge Fund Activity: Q1 2024 in Review
12 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q1 2024, worth a combined $43.8K — up 2.9% from $42.6K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SABSW positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $333. The largest seller was Morgan Stanley, cutting an estimated $4.01K.
- 12 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q1 2024, up from 10 in Q4 2023.
- Funds reported $43.8K of SAB Biotherapeutics Warrant stock for Q1 2024, up 2.9% quarter-over-quarter.
- 3 funds opened new SAB Biotherapeutics Warrant positions in Q1 2024 and 1 closed out, a net change of +2 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q1 2024 was Susquehanna International Group, an estimated $333 added.
- The largest SAB Biotherapeutics Warrant seller in Q1 2024 was Morgan Stanley, an estimated $4.01K sold.
Based on aggregated 13F filings for Q1 2024.